Citations

Clear

4847 citation(s) found for "Tu, Eric".

A Post-COVID Population-Based Analysis of Mohs Micrographic Surgeon Distribution in the United States
Olsen, Eric , Proffer, Sydney L. , DONNELLY, HEIDI B.

Mayo Clinic

Dermatologic Surgery | July 29, 2024 | Volume: 51 | Issue: 1 | Pages: 20-24

10.1097/dss.0000000000004356 | PMID 39074156 Get It

BACKGROUND Policy changes to Mohs micrographic surgery board certification eligibility and population shifts in the wake of the COVID-19 pandemic have significant implications for the accessibility of Mohs micrographic surgeons across the United States. OBJECTIVE To examine the geographic distribution of micrographic surgery providers considering recent population trends and assess the impact of certification eligibility changes and population shifts on accessibility. METHODS AND MATERIALS Medicare claims data were utilized to identify micrographic surgery providers. Surgeon densities were calculated per 100,000 people by county and state. Population changes were analyzed using US census data. RESULTS Practicing micrographic surgeons were concentrated in metropolitan and nonmetropolitan areas. Overall, 80.4% of counties lacked micrographic surgery providers, with rural areas being the most underserved. Population changes varied among states. CONCLUSION Shifts in micrographic surgery certification requirements, US population distribution, and micrographic surgeon location emphasize challenges in accessibility, especially in rural areas across the United States.
Impact of acute kidney injury response on survival and liver transplant rates in hospitalized patients with cirrhosis awaiting liver transplantation: Results from the HRS-HARMONY consortium
Ouyang, Tianqi , Belcher, Justin M. , Patidar, Kavish R. , Cullaro, Giuseppe , Wadei, Hani M. , Regner, Kevin R. , Dageforde, Leigh Anne , Przybyszewski, Eric M. , Duarte‐Rojo, Andrés , Wahid, Nabeel , Hillien, Shelsea A. St., Robinson, Jevon E., Allegretti, Andrew S. , Robinson, Jevon E. , Wadei, Hani M , Duarte-Rojo, Andres , Patidar, Kavish R , Cullaro, Giuseppe , Li, Xing , Asrani, Sumeet K. , Simonetto, Douglas A. , Wilechansky, Robert M. , Sharma, Pratima , Ufere, Nneka N , Orman, Eric S. , Chung, Raymond T.

Mayo Clinic

Liver Transplantation | July 29, 2024 | Volume: 30 | Issue: 11 | Pages: 1106-1115

10.1097/lvt.0000000000000445 | PMID 39073567 Get It

Acute kidney injury (AKI) frequently complicates the course of hospitalized patients with cirrhosis and negatively affects their prognosis. How AKI response influences the timing of liver transplantation (LT) remains unclear. We sought to assess the impact of AKI response to treatment on survival and LT rates in patients with cirrhosis awaiting LT. This was a retrospective multicenter study of cirrhosis patients waitlisted for LT and hospitalized with AKI in 2019. The exposure was AKI response versus no response during hospitalization. Outcomes were 90-day overall and transplant-free survival, and rates of LT with time to transplant. We adjusted for age, sex, race, cirrhosis etiology, site, and Model for End-Stage Liver Disease-Sodium (MELD-Na) score. Among the 317 patients in this study, 170 had an AKI response (53.6%), and 147 had no response (46.4%). Compared to nonresponders, responders had better 90-day overall survival (89.4% vs. 76.2%, adjusted subhazard ratio for mortality 0.34, p=0.001), and transplant-free survival (63.5% vs. 25.2%, aHR for probability of death or transplant 0.35, p<0.001). The LT rate was lower in responders (45.9% vs. 61.2%, adjusted subhazard ratio 0.55, p=0.005); 79% of transplants in responders occurred after discharge, at a median of 103 days, while 62% of transplants in nonresponders occurred during hospitalization, with the remainder occurring postdischarge at a median of 58 days. In patients with cirrhosis waitlisted for LT who are hospitalized with AKI, AKI response to therapy is associated with improved 90-day survival, despite a reduced LT rate and longer time to LT.
Correlations of Socioeconomic and Clinical Determinants with United States County‐Level Stroke Prevalence
Stulberg, Eric , Schneider, Andrea L.C. , Sarpong, Daniel F. , Wong, Ka-Ho , Sheth, Kevin N. , Stulberg, Eric L , Lisabeth, Lynda , Schneider, Andrea L C , Harris, Benjamin R.E., Sheth, Kevin N , Wong, Ka-Ho , Skolarus, Lesli E. , Kershaw, Kiarri N. , Zheutlin, Alexander R. , Harris, B. , Havenon, Adam de

Mayo Clinic

Annals of Neurology | July 26, 2024 | Volume: 96 | Issue: 4 | Pages: 739-744

10.1002/ana.27039 | PMID 39056317 Get It

Socioeconomic status (SES) is a multi‐faceted theoretical construct associated with stroke risk and outcomes. Knowing which SES measures best correlate with population stroke metrics would improve its accounting in observational research and inform interventions. Using the Centers for Disease Control and Prevention's (CDC) Population Level Analysis and Community Estimates (PLACES) and other publicly available databases, we conducted an ecological study comparing correlations of different United States county‐level SES, health care access and clinical risk factor measures with age‐adjusted stroke prevalence. The prevalence of adults living below 150% of the federal poverty level most strongly correlated with stroke prevalence compared to other SES and non‐SES measures (correlation coefficient = 0.908, R2 = 0.825; adjusted partial correlation coefficient: 0.589, R2 = 0.347). ANN NEUROL 2024;96:739–744
Ubiquitin-Proteasome System in the Different Stages of Dominantly Inherited Alzheimer’s Disease
McDade, Eric , Hassenstab, Jason , Gordon, Brian A. , Benzinger, Tammie L.S. , Shen, Yuanyuan , Wang, Lihua , Sung, Yun Ju , Daniels, Alisha , Xiong, Chengjie , Perrin, Richard J. , Day, Gregory S. , Chhatwal, Jasmeer P. , Huey, Edward D. , Ryan, Natalie S. , Laske, Christoph , Xiong, Chengjie , Roh, Jee Hoon , Lopera, Francisco , Morris, John C. , Gordon, Brian A , Benzinger, Tammie L S , Sung, Yun Ju , Karch, Celeste M , Renton, Alan , Day, Gregory S , Chhatwal, Jasmeer , Ikeuchi, T , Kasuga, Kensaku , Schofield, Peter R , Brooks, William , Xiong, Chengjie , Roh, Jee Hoon , Bateman, Randall J , Cruchaga, Carlos , Hassenstab, Jason , McDade, Eric M , Morris, John C , Liu, Haiyan , Bui, Quoc Van Phu , Timsina, Jigyasha , Karch, Celeste M. , Morris, John M. , Ibanez, Laura , Llibre‐Guerra, Jorge J. , Supnet, Charlene , Xu, Xiong, Berman, Sarah , Ikeuchi, Takeshi , Niimi, Yoshiki , Schofield, Peter R. , Brooks, William S. , Jucker, Mathias , Vöglein, Jonathan , Lopera, Francisco Javier , Bateman, Randall J.

Mayo Clinic

No container title available | July 23, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-4202125/v1 | PMID 39108475 Get It

Abstract This study explored the role of the ubiquitin-proteasome system (UPS) in dominantly inherited Alzheimer’s disease (DIAD) by examining changes in cerebrospinal fluid (CSF) levels of UPS proteins along with disease progression, AD imaging biomarkers (PiB PET, tau PET), neurodegeneration imaging measures (MRI, FDG PET), and Clinical Dementia Rating® (CDR®). Using the SOMAscan assay, we detected subtle increases in specific ubiquitin enzymes associated with proteostasis in mutation carriers (MCs) up to two decades before the estimated symptom onset. This was followed by more pronounced elevations of UPS-activating enzymes, including E2 and E3 proteins, and ubiquitin-related modifiers. Our findings also demonstrated consistent correlations between UPS proteins and CSF biomarkers such as Aβ42/40 ratio, total tau, various phosphorylated tau species to total tau ratios (ptau181/T181, ptauT205/T205, ptauS202/S202, ptauT217/T217), and MTBR-tau243, alongside Neurofilament light chain (NfL) and the CDR®. Notably, a positive association was observed with imaging markers (PiB PET, tau PET) and a negative correlation with markers of neurodegeneration (FDG PET, MRI), highlighting a significant link between UPS dysregulation and neurodegenerative processes. The correlations suggest that the increase in multiple UPS proteins with rising tau levels and tau-tangle associated markers, indicating a potential role for the UPS in relation to misfolded tau/neurofibrillary tangles (NFTs) and symptom onset. These findings indicate that elevated CSF UPS proteins in DIAD MCs could serve as early indicators of disease progression and suggest a link between UPS dysregulation and amyloid plaque, tau tangles formation, implicating the UPS as a potential therapeutic target in AD pathogenesis.
Outcomes in Stage IIA vs. Stage IIB/III in the PALLAS Trial [ABCSG-42/AFT-05/PrE0109/BIG-14-13])
Dueck, Amylou C. , Martín, Miguel, Burstein, H.J., Zdenkowski, Nick, Bellet-Ezquerra, M., Miller, Kathy, Lake, Diana, Rubovsky, Gabor, Cameron, D. , Singer, Christian, Nowecki, Zbigniew , Iwata, Hiroji, Parraga, Kepa Amilano, Rugo, Hope, Steger, Guenther G. , Theall, Kathy Puyana, Lu, Ray Dongrui, O’Brien, Patrick, Fesl, Christian , Bellet, Meritxell , Dueck, A. C. , DeMichele, Angela , Hlauschek, Dominik , Martı́n, Miguel , Pfeiler, GH, Zdenkowski, Nicholas , Wolff, Antonio C. , Winer, Eric P. , Balić, Marija , Miller, Kathy L. , Colleoni, Marco , Rubovsky, Gabor , Cameron, D., Balko, Justin M. , Singer, Christian F. , Iwata, Hiroji , Wolmark, Norman , Parraga, Kepa Amillano, Traina, Tiffany A , Werutsky, Gustavo , Czajkowska, D., Metzger, Otto , El-Abed, Sarra , Theall, K. P., O’Brien, P. , Mayer, E., Gnant, Michael

Mayo Clinic

No container title available | July 23, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-4612404/v1 Get It

Abstract Background The PALLAS trial investigated the addition of palbociclib to standard adjuvant endocrine therapy reduces breast cancer recurrence. This pre-specified analysis was conducted to determine whether adjuvant palbociclib benefited patients diagnosed with lower risk stage IIA disease compared to those with higher stage disease. Methods PALLAS was an international, multicenter, randomized, open-label, phase III trial, representing a public-private partnership between Pfizer, the Austrian Breast Cancer Study Group and, the U.S. ALLIANCE Foundation. Patients diagnosed with stage II-III, hormone-receptor-positive, HER2/neu negative breast cancer who were within 12 months of diagnosis, and had completed all definitive therapy aside from endocrine therapy, which was started within 6 months prior to study entry. All patients were required to submit a formalin-fixed paraffin-embedded (FFPE) tumor block. Patients were randomly assigned 1:1 to receive standard adjuvant endocrine therapy (of physicians’ choice) for at least 5 years with or without 2 years of Palbociclib, administered orally at a starting dose of 125 mg daily, given for 21 days followed by a 7-day break. Results A total of 5,796 patients with HR+/HER2- early breast cancer (including 1,010 with stage IIA) were enrolled. Median follow-up was 50 months for stage IIA patients and 43.1 months overall. In the stage IIA cohort, four-year iDFS in the palbociclib arm was 92.9% versus 92.1% for ET alone (HR 0.75, 95%CI 0.48–1.19, p = 0.23). There was no differential benefit by histologic grade, chemotherapy receipt, age, or anatomic/clinical risk. Additionally, no benefit to palbociclib was seen in this cohort in invasive breast cancer-free survival (iBCFS), locoregional relapse-free survival (LRFS), distant relapse-free survival (DRFS), or overall survival (OS). For the stage IIB/III patients, 4-year iDFS was 85.3% for palbociclib + ET versus 83.6% for ET alone (HR 0.91, 95% CI 0.77–1.07, p = 0.24). Conclusions and Relevance: While there were substantial differences in outcome for stage IIA versus IIB/III patients at 4 years of follow-up, the addition of 2 years of palbociclib did not improve outcomes for patients, regardless of stage. Trial Registration: The study was registered on Clinicaltrials.gov on July 31, 2015, and was assigned the clinical trial number (NCT02513394).
Harmonizing tau positron emission tomography in Alzheimer's disease: The CenTauR scale and the joint propagation model
Leuzy, Antoine , Villemagne, Victor L. , Klein, Gregory , Tonietto, Matteo, Olafson, Emily, Baker, Suzanne L. , Saad, Ziad S., Bullich, Santiago , Lopresti, Brian J. , Boada, Merçé , Charil, Arnaud , Collins, Emily C. , Collins, Jessica , Cullen, Nicholas , Gunn, Roger N. , Higuchi, Makoto , Hostetler, Eric D., Hutchison, R. Matthew , Irizarry, Michael C. , Jack, Clifford R. , Jagust, William J. , Karten, Yashmin, Marquié, Marta , Mathotaarachchi, Sulantha , Mintun, Mark A., Pappas, Ioannis , Petersen, Ronald C. , Rabinovici, Gil D. , Stephens, Andrew , Whittington, Alex , Carrillo, Marı́a C., Pontecorvo, Michael J. , Haeberlein, Samantha Budd , Dunn, Billy , Kolb, Hartmuth C. , Doré, Vincent , Carrillo, María C. , Jack, Clifford R , Boada, Merce , Rabinovici, Gil D , Doré, Vincent , Rakêt, Lars Lau , Tonietto, Mattéo , Bohórquez, Sandra Sanabria , Betthauser, Tobey J. , Iaccarino, Leonardo , Insel, Philip S. , Johnson, Sterling C. , Ossenkoppele, Rik , Rosa-Neto, Pedro , Schwarz, Christopher G. , Smith, Ruben , Sivakumaran, Sudhir , Rowe, Christopher Cleon , Hansson, Oskar

Mayo Clinic

Alzheimer's & Dementia | July 23, 2024 | Volume: 20 | Issue: 9 | Pages: 5833-5848

10.1002/alz.13908 | PMID 39041435 Get It

Abstract INTRODUCTION Tau‐positron emission tomography (PET) outcome data of patients with Alzheimer's disease (AD) cannot currently be meaningfully compared or combined when different tracers are used due to differences in tracer properties, instrumentation, and methods of analysis. METHODS Using head‐to‐head data from five cohorts with tau PET radiotracers designed to target tau deposition in AD, we tested a joint propagation model (JPM) to harmonize quantification (units termed “CenTauR” [CTR]). JPM is a statistical model that simultaneously models the relationships between head‐to‐head and anchor point data. JPM was compared to a linear regression approach analogous to the one used in the amyloid PET Centiloid scale. RESULTS A strong linear relationship was observed between CTR values across brain regions. Using the JPM approach, CTR estimates were similar to, but more accurate than, those derived using the linear regression approach. DISCUSSION Preliminary findings using the JPM support the development and adoption of a universal scale for tau‐PET quantification. Highlights Tested a novel joint propagation model (JPM) to harmonize quantification of tau PET. Units of common scale are termed “CenTauRs”. Tested a Centiloid‐like linear regression approach. Using five cohorts with head‐to‐head tau PET, JPM outperformed linearregressionbased approach. Strong linear relationship was observed between CenTauRs values across brain regions.
Oral Health Care for Children and Youth With Developmental Disabilities: Clinical Report
Sarvas, Elise , Webb, Jessica , Landrigan‐Ossar, Mary, Yin, Larry , HEALTH, SECTION ON ORAL, Beyer, Eric L., Brooks, Chevon, Feldman, Lauren , Kimball, C E, Tate, Anupama Rao , Unkel, John H. , Zaborowski, Matt, Crespin, Matt, Moursi, Amr M. , Beskin, Kera , Agrawal, Rishi , Bell, Deanna S. , Foster, Jessica E.A., Fremion, Ellen , Frierson, Sheryl, Melicosta, Michelle, Saunders, Barbara S. , Srivastava, Siddharth , Vargus‐Adams, Jilda , Kuo, Dennis Z. , Brosco, Jeffrey P. , Sadof, Matthew , Ware, Allysa , Yeargin-Allsopp, Marshalyn, Poon, Jennifer, Yeargin-Allsopp, Marshalyn, Kuznetsov, Alexandra , MEDICINE, SECTION ON ANESTHESIOLOGY AND PAIN, Chatterjee, Debnath , Diaz, Christina D. , Drum, Elizabeth T. , Sun, Lena S. , Willer, Brittany L. , Landrigan-Ossar, Mary, Fehr, James J. , Lin, Yuan‐Chi, Riefe, Jennifer, Sarvas, Elise W , HEALTH, SECTION ON ORAL, Karp, Jeffrey M. , Kimball, C. Eve, Sokal‐Gutierrez, Karen , Noritz, Garey H. , Zuckerman, Katharine E. , Weitzman, Carol Cohen , Yeargin-Allsopp, Marshalyn, Yeargin-Allsopp, Marshalyn, MEDICINE, SECTION ON ANESTHESIOLOGY AND PAIN, Long, Justin, Landrigan-Ossar, Mary, Adler, Adam C.

Mayo Clinic

Pediatrics | July 22, 2024 | Volume: 154 | Issue: 2 | Pages: No page available

10.1542/peds.2024-067603 | PMID 39034828 Get It

Oral health is an essential component of overall health for all individuals. The oral health of children and youth with developmental disabilities (CYDD) involves unique characteristics and needs of which pediatricians and pediatric clinicians can be aware. Risk for oral disease in CYDD is multifactorial and includes underlying medical conditions, medications, and ability to participate in preventive oral health care and treatment, and lack of access to providers is common for this population despite being eligible for Medicaid. Pediatric clinicians are uniquely positioned to support the oral health needs of CYDD and their families through the medical home. This clinical report aims to inform pediatric clinicians about the unique oral health needs of CYDD. It provides guidance on assessing caries risk and periodontal status using structured screening instruments; understanding dental trauma, the role of diet and caries risk, trauma prevention, and malocclusion; and providing anticipatory guidance on oral hygiene that includes tooth brushing, use of fluoridated toothpaste, assessing community water fluoridation, advocating for a dental home by 1 year of age, and transition to adult dental care as part of adolescent health care. It also highlights special considerations for dental treatment rendered under sedation or general anesthesia that CYDD may need. Pediatric clinicians can help reduce risk of CYDD developing dental disease by understanding the unique needs of their patients and their barriers to accessing oral health care in their community, communicating with the child’s dental home, and advocating for safe and accessible dental procedures.
Characterizing Neurobehavioral Dysregulation Among Former American Football Players: Findings From the DIAGNOSE CTE Research Project
Pulukuri, Surya , Fagle, Tessa, Trujillo‐Rodriguez, Diana , Amerongen, Suzan van , Bernick, Charles , Peskind, Elaine R. , Alosco, Michael L. , Palmisano, Joseph , Balcer, Laura J. , Reiman, Eric M. , Pulukuri, Surya V, Fagle, Tessa R, van Amerongen, Suzan, Pulukuri, Surya Vamsi , Geda, Yonas E. , Wethe, Jennifer V. , Katz, Douglas I. , Tripodis, Yorghos , Adler, Charles H. , Shenton, Martha E. , Cummings, Jeffrey L. , Stern, Robert A.

Mayo Clinic

The Journal of Neuropsychiatry and Clinical Neurosciences | July 22, 2024 | Volume: 37 | Issue: 1 | Pages: 38-46

10.1176/appi.neuropsych.20230133 | PMID 39034669 Get It

Exome Sequencing Identifies Carriers of the Autosomal Dominant Cancer Predisposition Disorders Beyond Current Practice Guideline Recommendations
Samadder, N. Jewel , Gay, E. Greer , Lindpere, Vanda , Bublitz, Michelle L. , Bandel, Lorelei A. , Armasu, Sebastian M. , Ferber, Matthew J. , Klee, Eric W. , Larson, Nicholas B. , Kruisselbrink, Teresa , Egan, Jan B. , Kemppainen, Jennifer L., Bidwell, Jessa , McAllister, Tammy M., Walker, T'Nita S., Klint, Margaret A., Presutti, R. John , Summer-Bolster, Jolene M., Gay, Emily , Klee, Eric W , Larson, Nicholas B , Kruisselbrink, Teresa M, Bidwell, Jessa S , Anderson, Jennifer L. , Kunze, Katie L , Golafshar, Michael A. , Presutti, Richard J , Bobo, William V. , Sekulic, Aleksander , Willman, Cheryl , Lazaridis, Konstantinos N , Lindpere, Vanda , Vierkant, Robert A. , Anderson, Jennifer L., Kunze, Katie L. , Klint, Margaret, Willman, Cheryl L. , Lazaridis, Konstantinos N.

Mayo Clinic

JCO Precision Oncology | July 16, 2024 | Volume: No volume available | Issue: 8 | Pages: No page available

10.1200/po.24.00106 | PMID 39013133 Get It

PURPOSE The autosomal dominant cancer predisposition disorders hereditary breast and ovarian cancer (HBOC) and Lynch syndrome (LS) are genetic conditions for which early identification and intervention have a positive effect on the individual and public health. The goals of this study were to determine whether germline genetic screening using exome sequencing could be used to efficiently identify carriers of HBOC and LS. METHODS Participants were recruited from three geographically and racially diverse sites in the United States (Rochester, MN; Phoenix, AZ; Jacksonville, FL). Participants underwent Exome+ sequencing (Helix Inc, San Mateo, CA) and return of results for specific genetic findings: HBOC ( BRCA1 and BRCA1) and LS ( MLH1, MSH2, MSH6, PMS2, and EPCAM). Chart review was performed to collect demographics and personal and family cancer history. RESULTS To date, 44,306 participants have enrolled in Tapestry. Annotation and interpretation of all variants in genes for HBOC and LS resulted in the identification of 550 carriers (prevalence, 1.24%), which included 387 with HBOC (27.2% BRCA1, 42.8% BRCA2) and 163 with LS (12.3% MSH6, 8.8% PMS2, 4.5% MLH1, 3.8% MSH2, and 0.2% EPCAM). More than half of these participants (52.1%) were newly diagnosed carriers with HBOC and LS. In all, 39.2% of HBOC/LS carriers did not satisfy National Comprehensive Cancer Network (NCCN) criteria for genetic evaluation. NCCN criteria were less commonly met in underrepresented minority populations versus self-reported White race (51.5% v 37.5%, P = .028). CONCLUSION Our results emphasize the need for wider utilization of germline genetic sequencing for enhanced screening and detection of individuals who have LS and HBOC cancer predisposition syndromes.
Outcomes of patients with alcohol‐associated hepatitis and acute kidney injury – Results from the HRS Harmony Consortium
T., Ann , Allegretti, Andrew S. , Cullaro, Giuseppe , Ouyang, Tianqui, Asrani, Sumeet K. , Przybyszewski, Eric M. , Robinson, Jevon E., Wadei, Hani M. , Hillien, Shelsea A. St., Saly, Danielle L. , Dageforde, Leigh Anne , Regner, Kevin R. , Belcher, Justin M. , Patidar, Kavish R. , Ma, Ann T , Ufere, Nneka N , Patidar, Kavish R , Asrani, Sumeet K , Wadei, Hani M , Cullaro, Giuseppe , Chung, Raymond T. , Wilechansky, Robert M. , Sharma, Pratima , Simonetto, Douglas A. , Jalal, Prasun K. , Orman, Eric S.

Mayo Clinic

Alimentary Pharmacology & Therapeutics | July 16, 2024 | Volume: 60 | Issue: 6 | Pages: 778-786

10.1111/apt.18159 | PMID 39010302 Get It

Summary Background & Aims The development of acute kidney injury (AKI) in the setting of alcohol‐associated hepatitis (AH) portends a poor prognosis. Whether the presence of AH itself drives worse outcomes in patients with cirrhosis and AKI is unknown. Methods Retrospective cohort study of 11 hospital networks of consecutive adult patients admitted in 2019 with cirrhosis and AKI. AKI phenotypes, clinical course, and outcomes were compared between AH and non‐AH groups. Results A total of 2062 patients were included, of which 303 (15%) had AH, as defined by National Institute on Alcohol Abuse and Alcoholism (NIAAA) criteria. Patients with AH, compared to those without, were younger and had higher Model for End‐stage Liver Disease‐Sodium (MELD‐Na) scores on admission. AKI phenotypes significantly differed between groups ( p < 0.001) with acute tubular necrosis occurring more frequently in patients with AH. Patients with AH reached more severe peak AKI stage, required more renal replacement therapy, and had higher 90‐day cumulative incidence of death (45% [95% CI: 39%–51%] vs. 38% [95% CI: 35%–40%], p = 0.026). Using no AH as reference, the unadjusted sHR for 90‐day mortality was higher for AH (sHR: 1.24 [95% CI: 1.03–1.50], p = 0.024), but was not significant when adjusting for MELD‐Na, age and sex. However, in patients with hepatorenal syndrome, AH was an independent predictor of 90‐day mortality (sHR: 1.82 [95% CI: 1.16–2.86], p = 0.009). Conclusions Hospitalised patients with cirrhosis and AKI presenting with AH had higher 90‐day mortality than those without AH, but this may have been driven by higher MELD‐Na rather than AH itself. However, in patients with hepatorenal syndrome, AH was an independent predictor of mortality.